AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06592898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: direct squat
Description: The subjects stood on the flat ground, the upper body was upright, the distance between feet was same as width of shoulder, and tiptoes were towards the front. The trunk was adjusted forward according to the Angle of static squat. The specific method is to adjust the trunk position to the line of the shoulder joint and knee joint perpendicular to the ground. Knee joint can bend at a large angle. The center of gravity was between the feet, put hands in front of body.The angle was set at 30° for the first two weeks, increased to 45° after two weeks, and set at 60° for the last two weeks.
Study NCT06231342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video laryngoscope (VL)
Description: VL facilitates intubation while allowing clinicians to share and record real-time high-resolution images and video.
Study NCT06592898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: wall squat assisted by elastic bands
Description: Based on wall squat, subjects put elastic band of 20 pounds between the thighs, open thighs and feet at a low speed, so that the elastic bands were slightly deformed and sence of resistance was obvious on the outside of the thighs.The angle was set at 30° for the first two weeks, increased to 45° after two weeks, and set at 60° for the last two weeks.
Study NCT06602973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rest
Description: Participants will eat breakfast but abstain from exercise
Study NCT06231342 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Tube (ETT) 180
Description: A novel maneuver has been described to decrease the insult from stylet named Endotracheal Tube (ETT) 180; a clockwise rotation of the stylet-loaded Endotracheal Tube (ETT) 180 degrees on its axis right after the tip of Endotracheal Tube (ETT) passes the patient's vocal cords (glottis) before fully inserting the Endotracheal Tube (ETT) and then, pulling the stylet out. This maneuverer allows the stylet to match the posterior angulation of the trachea.
Study NCT06602973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fed Exercise
Description: Participants will eat breakfast and engage in 30 minutes of physical activity at 75% of their personal V02max.
Study NCT06602973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasted Exercise
Description: Participants will engage in 30 minutes of physical activity at their personal 75% V02max after abstaining from breakfast.
Study NCT05751772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient therapeutic education
Description: The pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients is made by a clinical pharmacist and includes:~1. Targeted education on patient needs related to heart failure, heart failure medications and self-care;~2. a pre-discharge interview to consolidate key teaching messages and prepare the patient for their discharge treatment plan;~3. a telephone call the week of discharge to ensure pharmaceutical follow-up between hospital care and return home (continuity of care, transition of care).
Study NCT06592430 — intervention group
Intervention type: OTHER
Intervention: Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers
Description: Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers
Study NCT06592430 — intervention group
Intervention type: OTHER
Intervention: Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers
Description: Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers
Study NCT06601348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition education, physical activity intervention, and health promoting school model trials
Description: A nutrition education and physical activity intervention, combining a pilot health promoting school model that includes health education and recreational enhancement with the curriculum of a government-designated healthy school, was designed to reduce childhood overweight and obesity. The programme was implemented over 6 months. This program has been widely conducted in several countries, but there are still many differences from previous studies, especially in terms of strengthening qualitative studies in the first stage, then in the intervention stage using a Cluster Randomised Controlled Trial design. Another advantage of this study is the combination of intervention and health promoting school. In Indonesia, there are few intervention studies in reducing overweight and obesity in children, some only focus on descriptive studies such as nutritional knowledge, physical activity measures using questionnaires to determine the relationship or measure BMI.
Study NCT06591351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 MG
Description: Efficacy and safety of 200 mg cilostazol followed by 100 mg twice daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
Study NCT06591351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Efficacy and safety of 300 mg clopidogrel followed by 75mg once daily for three months and loading 300 mg aspirin and 75 mg aspirin maintenance will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects,
Study NCT06599151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FTC-146
Description: Adult participants will be injected with 5-10 mCi of \[18F\]FTC-146 and undergo a PET/MRI scan.
Study NCT06586333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stress ulcer prophylaxis
Description: In the EICU, patients were identified as part of the recruiting guideline group (GG), and in addition to receiving usual care, they were managed for SUP according to the ASHP SUP guidelines
Study NCT05522153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arista
Description: hemostatic powder
Study NCT06590090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrunix
Description: The active ingredient of Natrunix is an IgG4 monoclonal antibody indistinguishable from that naturally occurring in an IL-1a-immune healthy human.~Natrunix is formulated as 200 mg/mL sterile liquid in a stabilizing isotonic formulation buffered to pH 7.0. The product is filled into a 2 mL glass pre-filled syringe suitable for subcutaneous injection. The drug product is formulated and buffered to a neutral body pH of 7.0.
Study NCT06590090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a sterile liquid solution filled into a 2 mL glass pre-filled syringe, suitable for subcutaneous injection, containing the exact same buffer matrix used for Natrunix drug product
Study NCT06588881 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: nebulized application of the haemostatic surgical sealant after gastrointestinal endoscopic resection
Description: ENDONEB, a nebulizing catheter containing the synthetic haemostatic-sealant Glubran®, is inserted in the operative channel of the endoscope until it is pushed out of the endoscope tip approximately 2 cm. The haemostatic-sealant is nebulized over the surface of the post resection mucosal defect by activating the propellant (medical-inert-gas) container. An amount of about 0.3 mL of Glubran® 2 (or more - depending on dimension of the lesion) is applied on mucosal or sub-mucosal defect in order to create a proper haemostaticsealant film.
Study NCT06602505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A: Field Block Group
Description: Patients received field block with 5ml of 2% Lignocaine using a 24 G hypodermic needle before institution of subarachnoid block using 27 G Quincke's spinal needle for lower segment Caesarean section.
Study NCT06604208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Binaural Beats
Description: The binaural beat device is a health product that is not classified as a medical device. It functions similarly to a music box, providing different frequencies through physiological and psychological induction. This process offers binaural beat information to the Reticular Activating System (RAS) for potential changes in consciousness. The binaural beat frequencies are designed to match the brainwave frequency of light sleep, specifically 3.4 Hz (θ waves), with a base frequency of 440 Hz. The device uses three types of background music-piano music, light music, and string music-as experimental materials.~The binaural beat device offers three modes, allowing users to select different modes based on their comfort and listening preferences. This study requires that the binaural beats be listened to for at least 30 minutes. The device has a built-in app for continuous playback, so users can connect the power and listen throughout the night.
Study NCT06604208 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06591104 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24 hour urinary protein
Description: proteinuria and renal function impairment will be detected in patients of four groups
Study NCT06604182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based Simplified HCV Testing and Treatment Algorithm
Description: The distinctive features of CBSA are: (i) community-based service provision, substantially lowering the threshold for HCV services and eliminating the need to visit health care facilities for the majority of patients; (ii) the use of simple, once-daily, pan-genotypic HCV treatment regimens; (iii) a minimum of required laboratory tests and assessments; (iv) task sharing of essential functions from physicians to the case-managers; (v) integration of HCV testing and treatment with existing harm reduction services, addressing multiple health needs and facilitating patient-centered care.
Study NCT06654882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNFi (Tumor Necrosis Factor inhibitor) medication
Description: Adalimumab 10 kg (22 lbs) to \<15 kg (33 lbs) 10 mg every other week\* 15 kg (33 lbs) to \<30 kg (66 lbs) 20 mg every other week ≥30 kg (66 lbs) 40 mg every other week~Etanercept~≥63 kg (138 lb) 50 mg weekly \<63 kg (138 lb) 0.8 mg/kg weekly
Study NCT06654882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: 10 kg to \<25 kg 50 mg once weekly 25 kg to \<50 kg 87.5 mg once weekly~≥50 kg 125 mg once weekly
Study NCT06654882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: \<30 kg 162 mg once every 3 weeks~≥30 kg 162 mg once every 2 weeks
Study NCT06654882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: 10 to \<20 kg 3.2 mg (3.2 mL oral solution) BID 20 to \<40 kg 4 mg (4 mL oral solution) BID~≥40 kg 5 mg (one 5 mg tablet or 5 mL oral solution) BID
Study NCT06597721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-754
Description: Administered intravenously
Study NCT05134077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT scan with contrast
Description: CT scan with contrast is necessary to determine the position of renal cysts, their location, and size (determine volume of atrophic parenchyma will be calculated).
Study NCT05134077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT scan with contrast
Description: CT scan with contrast is necessary to determine the position of renal cysts, their location, and size (determine volume of atrophic parenchyma will be calculated).
Study NCT05134077 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Nephroscintigraphy
Description: Nephroscintigraphy is necessary to determine the renal function
Study NCT05134077 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Nephroscintigraphy
Description: Nephroscintigraphy is necessary to determine the renal function
Study NCT06261164 — intervention group
Intervention type: DEVICE
Intervention: Cytosorb® and Oxiris® adsorbents
Description: The pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.
Study NCT06587672 — intervention group
Intervention type: DEVICE
Intervention: Micra AV implantation
Description: Patients received Micra AV implantation
Study NCT06586866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK-1201I
Description: JK-1201I will be administered as an IV infusion at dose of 125mg/m2 on Day 1 of each 14-day cycle.
Study NCT05156567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Deep Learning System
Description: The multitask DLS with five algorithms detecting spine metastases and evaluate features (bone lesion quality, posterolateral involvement, and vertebral body collapse)
Study NCT06601725 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clusterin level
Description: Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis
Study NCT06598657 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization with Movement MWM
Description: Mobilization with Movement MWM of Talocrural joint in non-weight bearing position to improve Dorsiflexion Range of Motion (3 sets of 6 repetitions were applied, with a 1-minute break between sets/3 times a week) and conventional therapy which includes stretching, strengthening, balance training exercise.
Study NCT06598657 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Treatment
Description: * Stretches of Hamstrings, Gastrocnemius, Soleus and hip adductors with duration of 20 sec hold/ 5 reps and Frequency: 3 times/week. Stretches will be performed passively~* Strengthening exercises of Quadriceps and abdominal muscles three times a week.~* Static balance exercises including single leg balance, tandem stance, weight shifting with Duration: 10 sec hold/ 5 reps Frequency: 3 times/week
Study NCT06599437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: Early laparoscopic cholecystectomy in the same admission after atone clearance from the bile ducts via ERCP.
Study NCT06599437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy is performed 6 weeks after clearance of stones from the common bile duct.
Study NCT06592105 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular aortic aneurysm repair (EVAR)
Description: Intervention description: - patients who underwent elective EVAR for non-ruptured AAA for the first time, - patients who underwent non-complex EVAR procedure with commercially available endografts with CE mark, - patients with non-syndromic AAA or with non-infective AAA, - patients aged more than 18 years old.
Study NCT06603545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital education for osteoporosis patients
Description: DEOP is found on the Swedish health care system's dedicated website or app 1177, it takes approximately 60 minutes to complete and is composed of three modules: 1)Introduction: an animated video that shows the patient flow from having a fracture, being evaluated at the osteoporosis clinic, receiving information about osteoporosis, and being treated for osteoporosis. 2)Osteoporosis: basic information about osteoporosis; why it occurs, risk factors that the patient can affect (such as physical inactivity and smoking), and risk factors that cannot be affected (such as age and heredity). It provides information about typical osteoporotic fractures, and how a patient is evaluated according to clinical guidelines for osteoporosis care. 3)Treatment: information about the different kinds of pharmacological osteoporosis treatment, physical activity, balance control, lifting technique, risk of falling, and dietary advice, especially regarding calcium and vitamin D intake.
Study NCT06588998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xengenic Cortical membranes
Description: soft tissue surgery around dental implant dehiscence
Study NCT06588998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft
Description: soft tissue surgery around dental implant dehiscence
Study NCT06592950 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Online survey
Study NCT06592950 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Interviews
Study NCT06590714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental(Acelex cap m2mg)
Description: Experimental Arm (Polmacoxib (Acelex cap 2mg + NSAIDs-excluded non-opioid or opioid analgesics))~Polmacoxib (preventive Acelex cap 2mg) administered, dosage: 1 tablet orally once daily, regardless of meals.~NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN).
Study NCT06590714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator(NSAIDs-excluded non-opioid or opioid analgesics)
Description: NSAIDs-excluded non-opioid or opioid analgesics, dosage: as needed (PRN).
Study NCT06587646 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Virtual Examination under Anaeastehtic - 3D reconstruction imaging
Description: 3D reconstruction of MRI imaging and review by patient and surgeon prior to surgical intervention.
Study NCT06587646 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care - Written MRI report
Description: A standard written MRI report will be provided to the surgeon and patient prior to surgical intervention.
Study NCT06586463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinitic control training
Description: kinetic control training, Correction of Low cervical flexion UCM Initially, position the lower and upper cervical spine in neutral with the head supported. the person is trained to perform independent upper cervical flexion (nodding). The upper cervical spine can flex only so far as there is no low cervical flexion. As the ability to control upper cervical extension gets easier and the pattern of dissociation feels less unnatural the exercise can be progressed.~Correction of scapula and glenohumeral ( UCM) the arm flexion is performed unsupported through the partial range that can be controlled well. This is eventually progressed throughout the full benchmark range with the elbow straight. With visual, auditory and kinaesthetic cues the person becomes familiar with the task of flexing the glenohumeral joint to 90° without scapula movement or glenohumeral translation.
Study NCT06586463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinitic control training
Description: kinetic control training, Correction of Low cervical flexion UCM Initially, position the lower and upper cervical spine in neutral with the head supported. the person is trained to perform independent upper cervical flexion (nodding). The upper cervical spine can flex only so far as there is no low cervical flexion. As the ability to control upper cervical extension gets easier and the pattern of dissociation feels less unnatural the exercise can be progressed.~Correction of scapula and glenohumeral ( UCM) the arm flexion is performed unsupported through the partial range that can be controlled well. This is eventually progressed throughout the full benchmark range with the elbow straight. With visual, auditory and kinaesthetic cues the person becomes familiar with the task of flexing the glenohumeral joint to 90° without scapula movement or glenohumeral translation.
Study NCT06590896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: Cenobamate will be orally administered once daily.
Study NCT06595524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online mindfulness-based intervention
Description: The mindfulness-based intervention (MFU-Mindful-application) consists of 8 topics, one topic per week. Moreover, we will assign participants (experimental group) to continuously practice using guided meditation approximately 10 minutes daily at least 5 days a week for 3 months via MFU-Mindful application
Study NCT06586632 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AID technology
Description: Automated insulin delivery system combined with a CGM
Study NCT06586632 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CGM
Description: CGM alone
Study NCT06600828 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data collected: Socio-demographic, hospital, clinical, biological, and imaging data
Study NCT06589856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (300 mL salt water, NaCl) = CTR
Study NCT06589856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (300 mL salt water, NaCl) = CTR
Study NCT06589856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LAC5
Description: 5 g lactate (300 mL lactate drink = 5 g D/L-lactate bound to Na) = LAC5
Study NCT06589856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LAC5
Description: 5 g lactate (300 mL lactate drink = 5 g D/L-lactate bound to Na) = LAC5
Study NCT06589856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LAC10
Description: 10 g lactate (300 mL lactate drink = 10 g D/L-lactate bound to Na) = LAC10
Study NCT06589856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LAC10
Description: 10 g lactate (300 mL lactate drink = 10 g D/L-lactate bound to Na) = LAC10
Study NCT06589856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LAC20
Description: 20 g lactate (300 mL lactate drink = 20 g D/L-lactate bound to Na) = LAC20
Study NCT06589856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LAC20
Description: 20 g lactate (300 mL lactate drink = 20 g D/L-lactate bound to Na) = LAC20